类风湿关节炎中的克霉唑。
Clotrimazole in rheumatoid arthritis.
作者信息
Wojtulewski J A, Gow P J, Walter J, Grahame R, Gibson T, Panayi G S, Mason J
出版信息
Ann Rheum Dis. 1980 Oct;39(5):469-72. doi: 10.1136/ard.39.5.469.
Abstract
Forty-seven patients with active rheumatoid arthritis took part in an 8-week controlled study in which clotrimazole was compared with a standard nonsteroidal anti-inflammatory agent, ketoprofen. Although clotrimazole was shown to be effective in the treatment of the disease and superior to ketoprofen in certain measurements, if was also responsible for a high incidence of adverse effects. Improvement with clotrimazole took place more slowly but was more sustained than with ketoprofen. A significant rise in plasma cortisol and a fall in white cell count was observed in the clotrimazole treated patients.
摘要
47名活动性类风湿性关节炎患者参与了一项为期8周的对照研究，该研究将克霉唑与标准非甾体抗炎药酮洛芬进行了比较。尽管克霉唑被证明对该疾病有效，且在某些测量指标上优于酮洛芬，但它也导致了高不良反应发生率。与酮洛芬相比，克霉唑的改善起效更慢，但更持久。在接受克霉唑治疗的患者中观察到血浆皮质醇显著升高和白细胞计数下降。
相似文献
1
Clotrimazole in rheumatoid arthritis.类风湿关节炎中的克霉唑。
Ann Rheum Dis. 1980 Oct;39(5):469-72. doi: 10.1136/ard.39.5.469.
2
A double blind placebo controlled trial of low dose clotrimazole in rheumatoid arthritis.低剂量克霉唑治疗类风湿性关节炎的双盲安慰剂对照试验。
J Rheumatol. 1990 Aug;17(8):1003-7.
3
The effect of clotrimazole on human lymphocyte responsiveness to plant mitogens.
Agents Actions. 1979 Dec;9(5-6):543-8. doi: 10.1007/BF01968125.
4
Clotrimazole treatment of oral candidiasis in patients with neoplastic disease.克霉唑治疗肿瘤疾病患者的口腔念珠菌病。
Am J Med. 1984 Jan;76(1):91-4. doi: 10.1016/0002-9343(84)90755-1.
5
Letter: Clotrimazole and rheumatoid arthritis.信件：克霉唑与类风湿性关节炎
Lancet. 1976 Feb 28;1(7957):489. doi: 10.1016/s0140-6736(76)91516-6.
6
Letter: Clotrimazole and rheumatoid arthritis.信函：克霉唑与类风湿关节炎
Lancet. 1976 Jan 17;1(7951):148. doi: 10.1016/s0140-6736(76)93190-1.
7
[Limitations of indications of clotrimazole-hydrocortisone and its components. A double-blind study].[克霉唑-氢化可的松及其成分适应症的局限性。一项双盲研究]
Arzneimittelforschung. 1984;34(8):927-30.
8
Clinical evaluation of clotrimazole. A broad-spectrum antifungal agent.克霉唑的临床评估。一种广谱抗真菌剂。
Arch Dermatol. 1976 Mar;112(3):350-2.
9
[A clinical study of cyclopyroxolamine versus clotrimazole in the treatment of mycotic vulvovaginitis].环吡酮胺与克霉唑治疗霉菌性外阴阴道炎的临床研究
Minerva Med. 1990 Jul-Aug;81(7-8):555-9.
10
A double-blind crossover evaluation of ketoprofen (Orudis) and placebo in rheumatoid arthritis with assessment of long-term tolerance.酮洛芬（奥鲁地）与安慰剂治疗类风湿性关节炎的双盲交叉评估及长期耐受性评价
J Int Med Res. 1978;6(4):300-5. doi: 10.1177/030006057800600407.
引用本文的文献
1
Role of Calcium-Activated Potassium Channels in Proliferation, Migration and Invasion of Human Chronic Myeloid Leukemia K562 Cells.钙激活钾通道在人慢性髓性白血病K562细胞增殖、迁移和侵袭中的作用
Membranes (Basel). 2023 Jun 4;13(6):583. doi: 10.3390/membranes13060583.
2
Bibliometrics analysis on the research status and trends of adult-onset Still's disease: 1921-2021.基于文献计量学的成人斯蒂尔病研究现状与趋势分析：1921-2021 年。
Front Immunol. 2022 Jul 18;13:950641. doi: 10.3389/fimmu.2022.950641. eCollection 2022.
3
Ca signalling in fibroblasts and the therapeutic potential of K3.1 channel blockers in fibrotic diseases.成纤维细胞中的钙信号转导及 K3.1 通道阻滞剂在纤维化疾病中的治疗潜力。
Br J Pharmacol. 2020 Mar;177(5):1003-1024. doi: 10.1111/bph.14939. Epub 2020 Feb 3.
4
7α, 25-dihydroxycholesterol-mediated activation of EBI2 in immune regulation and diseases.7α,25-二羟基胆固醇介导的EBI2在免疫调节和疾病中的激活作用
Front Pharmacol. 2015 Mar 24;6:60. doi: 10.3389/fphar.2015.00060. eCollection 2015.
5
The Lymphocyte Potassium Channels Kv1.3 and KCa3.1 as Targets for Immunosuppression.淋巴细胞钾通道Kv1.3和KCa3.1作为免疫抑制靶点
Drug Dev Res. 2011 Nov;72(7):573-584. doi: 10.1002/ddr.20467.
6
Therapeutic potential of KCa3.1 blockers: recent advances and promising trends.KCa3.1 通道阻滞剂的治疗潜力：最新进展与前景趋势。
Expert Rev Clin Pharmacol. 2010 May;3(3):385-96. doi: 10.1586/ecp.10.11.
7
Control of hypothalamic-pituitary-adrenal stress axis activity by the intermediate conductance calcium-activated potassium channel, SK4.中间电导钙激活钾通道 SK4 对下丘脑-垂体-肾上腺应激轴活动的控制。
J Physiol. 2011 Dec 15;589(Pt 24):5965-86. doi: 10.1113/jphysiol.2011.219378. Epub 2011 Oct 31.
8
The intermediate-conductance calcium-activated potassium channel KCa3.1 contributes to atherogenesis in mice and humans.中电导钙激活钾通道KCa3.1在小鼠和人类动脉粥样硬化形成过程中发挥作用。
J Clin Invest. 2008 Sep;118(9):3025-37. doi: 10.1172/JCI30836.
9
K+ channel modulators for the treatment of neurological disorders and autoimmune diseases.用于治疗神经疾病和自身免疫性疾病的钾离子通道调节剂。
Chem Rev. 2008 May;108(5):1744-73. doi: 10.1021/cr078234p.
10
Functional KCa3.1 K+ channels are required for human lung mast cell migration.功能性KCa3.1钾通道是人类肺肥大细胞迁移所必需的。
Thorax. 2006 Oct;61(10):880-5. doi: 10.1136/thx.2006.060319. Epub 2006 Jun 29.
本文引用的文献
1
DIAGNOSTIC criteria for rheumatoid arthritis: 1958 revision by a committee of the American Rheumatism Association.类风湿关节炎的诊断标准：美国风湿病协会委员会1958年修订版。
Ann Rheum Dis. 1959 Mar;18(1):49-51; French transl 51-2; Spanish transl 52-3.
2
Nitro-imidazole in rheumtoid arthritis.类风湿关节炎中的硝基咪唑
J Trop Med Hyg. 1972 Mar;75(3):64-6.
3
4
Clinical measurement of the anti-inflammatory effects of salicylates in rheumatoid arthritis.水杨酸酯类药物在类风湿关节炎中抗炎作用的临床测量
Br Med J. 1967 Nov 4;4(5574):264-8. doi: 10.1136/bmj.4.5574.264.
5
Double-blind cross-over study of Orudis and placebo in fifty patients with rheumatoid arthritis.奥鲁地（Orudis）与安慰剂治疗五十例类风湿性关节炎患者的双盲交叉研究。
Rheumatol Rehabil. 1973 May;12(2):62-7. doi: 10.1093/rheumatology/12.2.62.
6
Orudis in management of rheumatoid arthritis and osteoarthrosis of the hip: comparison with indomethacin.奥鲁地司用于治疗类风湿性关节炎和髋关节骨关节炎：与消炎痛的比较。
Br Med J. 1972 Nov 18;4(5837):398-400. doi: 10.1136/bmj.4.5837.398.
7
Letter: Clotrimazole and rheumatoid arthritis.信件：克霉唑与类风湿性关节炎
Lancet. 1976 Feb 28;1(7957):489. doi: 10.1016/s0140-6736(76)91516-6.
8
Immunostimulant therapy with levamisole for rheumatoid arthritis.
Lancet. 1976 Feb 21;1(7956):393-5. doi: 10.1016/s0140-6736(76)90218-x.
9
Letter: Clotrimazole and rheumatoid arthritis.信函：克霉唑与类风湿关节炎
Lancet. 1976 Jan 17;1(7951):148. doi: 10.1016/s0140-6736(76)93190-1.
Zotero 插件